Pharmena S.A. (WSE:PHR)

Poland · Delayed Price · Currency is PLN

3.160

+0.010 (0.32%)

Jul 3, 2026, 5:00 PM CET

-4.24% (1Y)

Market Cap	35.20M -7.1%
Revenue (ttm)	1.61M +146.5%
Net Income	-2.76M
EPS	-0.25
Shares Out	11.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.85 (26.90%)
Ex-Dividend Date	n/a

Volume	85
Open	3.090
Previous Close	3.150
Day's Range	3.090 - 3.170
52-Week Range	2.500 - 4.320
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Pharmena

Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. It also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, the company is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. Pharmena S.A. was ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 7

Stock Exchange Warsaw Stock Exchange

Ticker Symbol PHR

Full Company Profile

Financial Performance

In 2025, Pharmena's revenue was 1.58 million, an increase of 488.43% compared to the previous year's 268,000. Losses were -2.77 million, 119.4% more than in 2024.

Financial Statements